Forte Biosciences (FBRX) Net Income towards Common Stockholders (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Net Income towards Common Stockholders of -$22.1 million for Q1 2026, down 41.39% year-over-year from -$37.8 million in Q1 2025, and up 10.07% quarter-over-quarter from -$24.6 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Net Income towards Common Stockholders for 11 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 41.39% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$107.2 million (down 140.3% YoY), while the FY2025 annual figure was -$73.5 million, down 2655.51% from the prior year.
- Net Income towards Common Stockholders grew to -$22.1 million in Q1 2026 per FBRX's latest filing, from -$24.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.8 million in Q1 2022 and bottomed at -$35.8 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$12.2 million across 5 years, with a median of -$8.7 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 90.32% — and 2025, when it plunged 313.47%.
- Forte Biosciences' Net Income towards Common Stockholders stood at -$5.0 million in 2022, then decreased by 28.12% to -$6.4 million in 2023, then slipped by 15.93% to -$7.4 million in 2024, then slumped by 231.19% to -$24.6 million in 2025, then climbed by 10.07% to -$22.1 million in 2026.
- Business Quant data shows FBRX's Net Income towards Common Stockholders at -$22.1 million in Q1 2026, -$24.6 million in Q4 2025, and -$35.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | -23.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.33 Mn |
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -24.57 Mn |
| Sep 30, 2025 | -18.38 Mn |
| Jun 30, 2025 | -11.25 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | -7.35 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | -12.82 Mn |
| Mar 31, 2024 | -7.80 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.03 Mn |
| Mar 31, 2023 | -6.86 Mn |
| Dec 31, 2022 | -4.94 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -7.70 Mn |